Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
Published in 2023 by
Erika J. Lampert,
Alexandra Zimmer 
,
Michelle Padget,
Ashley Cimino-Mathews,
Jayakumar R. Nair,
Yingmiao Liu,
Elizabeth M. Swisher,
James W. Hodge,
Andrew B. Nixon ,
Erin Nichols,
Mohammad H. Bagheri,
Elliott Levy,
Marc R. Radke,
Stanley Lipkowitz,
Christina M. Annunziata
and other authors.
,
Michelle Padget,
Ashley Cimino-Mathews,
Jayakumar R. Nair,
Yingmiao Liu,
Elizabeth M. Swisher,
James W. Hodge,
Andrew B. Nixon ,
Erin Nichols,
Mohammad H. Bagheri,
Elliott Levy,
Marc R. Radke,
Stanley Lipkowitz,
Christina M. Annunziata
and other authors.
